A phase 3, multi-centre, randomised, double-blinded trial of favipiravir versus placebo for treatment of mild Covid-19 in outpatients in South Africa (FATE Trial)
- Funded by Department of Science and Innovation - South Africa
- Total publications:0 publications
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$140,000Funder
Department of Science and Innovation - South AfricaPrincipal Investigator
N/A
Research Location
South AfricaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Phase 3 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase III
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified